Statistically significant lower risk is seen for mortality, ventilation, ICU admission, progression, and viral clearance. 15 studies from 13 independent teams in 2 countries show significant improvements.
Meta analysis using the most serious outcome reported shows 33% [18‑44%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and peer-reviewed studies.
Results are robust — in exclusion sensitivity analysis 10 of 22 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.
No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective.
All data to reproduce this paper and sources are in the appendix. 4 other meta analyses show significant improvements with azvudine for mortality1-4, mechanical ventilation1, clinical improvement1, and viral clearance1,3,4.
4 meta analyses show significant improvements with azvudine for mortality
1-4,
mechanical ventilation
1,
improvement
1, and
viral clearance
1,3,4.
Covid Analysis et al., Sep 2024, preprint, 1 author.
